Piper Jaffray Tidbits From Salix Management

Piper Jaffray has published a research report following meetings with Salix Pharmaceuticals SLXP management. In the report, Piper Jaffray writes "We had the opportunity to spend time with Salix senior management in meetings with investors. Management reiterated its 3-year aspirational goal of total revenue meeting/exceeding $1B. Importantly, comments from management on margins and its expense structure reinforced our view that Street EPS estimates for 2011 and later years are conservative. We continue to believe that EPS well north of $3 per share in 2012 and north of $5 per share in 2013 is realistic, translating into one of the most compelling long-term earnings growth trajectories in the specialty pharma space." Piper Jaffray reiterates its Overweight rating and $58 price target. Salix Pharmaceuticals closed yesterday at $39.72